Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Novartis AG ADS (NY: NVS)
73.12 USD  -0.17 (-0.23%)
Official Closing Price  /  Updated: 6:40 PM EDT, Jun 18, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Novartis AG ADS
 
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Pawfect Foods Announces Acquisition of Synergy Pharmaceuticals and $3.0 Million Financing
July 21, 2008
Files Charter Amendment to Split Stock and Change Corporate Name Read More
from Business Wire News Releases
Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day
July 08, 2008
- Focalin XR demonstrated better symptom control versus Concerta from 30 minutes to six hours post-dose in primary and secondary endpoints Read More
from PR Newswire
Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
July 01, 2008
Jury verdict in Montgomery County Circuit Court awards $33 million in compensatory damages Read More
from PR Newswire
BellwetherReport.com Analyst Report on KR, CTL, NVS and IPI
June 24, 2008
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by The Bellwether Report. Read More
from Marketwired News Releases
Seven Summits Research Releases Comments on V, AMZN, NVS, EK, and TIF
June 24, 2008
from PR Newswire
New Analyst Reports for GOLDSOURCE MINES INC, PURE ENERGY SERVICES LTD, NOVARTIS AG, and CITIZENS COMMUNICATIONS CO
June 18, 2008
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Maybach. Read More
from Marketwired News Releases
Zacks Analyst Interview Highlights: Syngenta, Novartis, AstraZeneca and Monsanto
June 18, 2008
from Business Wire News Releases
Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
June 13, 2008
- Efficacy and safety profile in large randomized Phase III study consistent with landmark IRIS trial, which established Gleevec as standard of care Read More
from PR Newswire
FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
June 05, 2008
- Revised label includes data showing 35% reduction in new clinical fractures in patients treated with Reclast following a recent hip fracture(1) Read More
from PR Newswire
Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
June 02, 2008
- Randomized Phase II data show RAD001 significantly increased efficacy of letrozole tablets in women with newly diagnosed hormone-positive breast cancer Read More
from PR Newswire
Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
May 31, 2008
- Zometa when added to hormone therapy, following surgery, significantly reduced the risk of cancer returning or death by 36% beyond clinical benefits achieved with hormone therapy alone(1) Read More
from PR Newswire
Dutton Associates Announces Investment Opinion: NexMed Strong Speculative Buy Rating Maintained By Dutton Associates
May 29, 2008
from Business Wire News Releases
Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
May 19, 2008
from PR Newswire
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
May 19, 2008
- RECORD-1 trial shows RAD001 reduces risk of disease progression by 70% Read More
from PR Newswire
Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
May 15, 2008
- Unprecedented amount of research reflects depth and breadth of collaboration with investigators worldwide to develop new treatments for diverse forms of cancer Read More
from PR Newswire
Seven Summits Research Releases Comments on RIG, HES, URBN, BCS, and NVS
May 15, 2008
from PR Newswire
In a Phase II Study, Novartis Meningitis B Vaccine Has Potential to Produce a Protective Immune Response in Infants, the Age Group Most at Risk
May 14, 2008
from Marketwired News Releases
BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial
May 06, 2008
A Milestone Reached to Commercialize Leading OAB Drug in China Read More
from PR Newswire
Introgen Therapeutics, Inc. Expands Board of Directors
April 17, 2008
Former Pharmaceutical Veteran Brings Extensive Management Experience to Introgen Read More
from Business Wire News Releases
Anavex appoints Dr. Dimitri Goundis to lead Clinical Development
April 16, 2008
from PR Newswire
FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
April 15, 2008
- Phase II study extension shows 68-73% of patients with multiple sclerosis remained relapse-free after three years of treatment with oral FTY720 Read More
from PR Newswire
Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids
April 11, 2008
- Glucocorticoids, commonly known as steroids, widely used to treat inflammatory conditions but can increase the risk of osteoporotic fractures with up to 50% of patients on long-term therapy at... Read More
from PR Newswire
Seven Summits Research Releases Comments on C, MOS, ESLR, MGM, and NVS
April 07, 2008
from PR Newswire
Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
March 31, 2008
- ACCOMPLISH first study to compare two single-pill combinations of commonly used high blood pressure medicines in reduction of cardiovascular events Read More
from PR Newswire
Seven Summits Research Releases Comments on GRMN, DE, ERTS, PCU, and NVS
March 25, 2008
from PR Newswire
IR Global Rankings Announces 2008 Benchmarks and Winners for Europe
March 24, 2008
from PR Newswire
2008 IR Global Rankings Workshops and Award Ceremonies
March 14, 2008
from PR Newswire
Stonegate Report About Unigene Laboratories Inc.
March 13, 2008
from PR Newswire
VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
March 10, 2008
- Post-unblinding analysis of MA-17 trial data provides evidence for potential benefit of starting Femara up to seven years after finishing tamoxifen Read More
from PR Newswire
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
February 28, 2008
- Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus Read More
from PR Newswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here